Co-Dafalgan
Co-Dafalgan is a medicine authorised by Swissmedic under authorisation number 47353. The authorisation holder is UPSA Switzerland AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 03 December 1986 and the authorisation is valid without a time limit. ATC code N02AJ06 places the medicine in the group Analgesics.
| Authorisation number | 47353 |
|---|---|
| Name | Co-Dafalgan |
| Full name | Co-Dafalgan, Brausetabletten |
| Authorisation holder | UPSA Switzerland AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | N02AJ06 |
| First authorisation | 03 December 1986 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Co-Dafalgan, Brausetabletten | B | 03 December 1986 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 25 | 16 | Tablette(n) | N02AJ06 | 01.01.2. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Co-Dafalgan authorised in Switzerland?
Yes. Co-Dafalgan is authorised by Swissmedic under authorisation number 47353, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Co-Dafalgan have?
Co-Dafalgan is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Co-Dafalgan?
The authorisation holder is UPSA Switzerland AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.